组织型转谷氨酰胺酶在后囊膜混浊中的作用研究
|
摘要
第一部分tTG抑制剂对人晶状体上皮细胞表达FN、Col-Ⅳ的影响研究
目的观察组织型转谷氨酰胺酶(tissue transglutaminase, tTG)抑制剂单丹磺酰尸胺monodansyl-cadaverine (MDC)对转化生长因子β2 (transforming growth factor-β2, TGF-β2)诱导的人晶状体上皮细胞(Human lens epithelial cells, HLECs)表达纤维连接蛋白(Fibrone-ctin, FN)和Ⅳ型胶原(collagenⅣ, Col-Ⅳ)的影响。
方法将体外培养的人晶状体上皮细胞株HLE-B3分为5组：无血清培养基中培养的HLE-B3为正常对照组；加入10μg/L TGF-β2处理36h的HLE-B3为TGF-p2组;10μg／LTGF-p2与100、200和400μmol/L MDC共同处理36h的HLE-B3为不同浓度MDC组。用半定量RT-PCR检测tTG、FN、Col-Ⅳ在HLE-B3细胞中表达的变化。
结果正常体外培养的HLE-B3细胞中可表达一定量的tTG, FN及Col-Ⅳ。与正常对照组相比,TGF-β2组中tTG, FN和Col-Ⅳ的表达明显增强,差异有统计学意义(P<0.01)。与TGF-β2组相比,100、200和400μmol/L MDC组中FN和Col-Ⅳ的表达含量明显减少(P<0.01)。100、200和400μmol/L MDC组各组间FN和Col-Ⅳ的表达差异亦具有显著性意义(P<0.01)。
结论MDC可剂量依赖性的抑制TGF-p2诱导的LECs中FN和Col-Ⅳ表达的增加。tTG可能通过促进HLECs表达FN和Col-Ⅳ等细胞外基质成分参与白内障术后后囊膜混浊(posterior capsule opacification, PCO)的形成。
第二部分RNA干扰对人晶状体上皮细胞tTG表达的影响研究
目的研究RNA干扰抑制组织型转谷氨酰胺酶(tissue transglutaminase, tTG)对人晶状体上皮细胞(Human lens epithelial cells, HLECs)中tTG表达的影响。
方法设计并合成特异性针对tTG的3对小干扰RNA(short interfering RNA, siRNA): siRNA-1、siRNA-2、siRNA-3,用Real-time RT-PCR和Western blot法检测转染了siRNA后人晶状体上皮细胞株(HLE-B3)中tTG基因在mRNA水平和蛋白水平的变化。
结果转染siRNA-1、siRNA-2、siRNA-348h后,tTG mRNA的表达分别下降为空白对照组的46.60%,12.84%,66.75%,与空白对照组相比差异具有统计学意义(P<0.05)。转染siRNA-1、siRNA-2、siRNA-360h后,tTG蛋白的表达含量分别下降为空白对照组的60.49%,27.87%,55.91%(P<0.01)。Real-time RT-PCR与Western blot检测结果一致显示了siRNA-2对tTG基因的抑制效果最佳。
结论我们设计并合成的靶向tTG的siRNA可以显著降低tTG的表达。
第三部分tTG-siRNA对人晶状体上皮细胞转分化和细胞外基质沉积的作用研究
目的探讨RNA干扰抑制组织型转谷氨酰胺酶(tissue transglutaminase, tTG)的表达对人转化生长因子β2(transforming growth factorβ2, TGF-β2)诱导的人晶状体上皮细胞(Human lens epithelial cells, HLECs)转分化和细胞外基质沉积的抑制作用。
方法将体外培养的人晶状体上皮细胞株HLE-B3分为正常对照组,TGF-β2组和TGF-β2+siRNA组。Western blot法检测各组细胞tTG、α平滑肌肌动蛋白(a-Smooth muscle actin, a-SMA)、纤维连接蛋白(Fibronectin, FN)和Ⅳ型胶原(collagen IV, Col-IV)的表达。
结果与正常对照组相比,TGF-β2组中tTG、α-SMA、FN、Col-Ⅳ的表达量均明显增加(P<0.01)；与TGF-β2组相比,TGF-β2+siRNA组中tTG、α-SMA、FN、Col-Ⅳ的表达量均明显减少(P<0.01)。
结论靶向tTG的siRNA可以明显抑制TGF-β2诱导的HLE-B3细胞合成a-SMA、FN、Col-Ⅳ。提示tTG是介导TGF-β2诱导人晶状体上皮细胞转分化和细胞外基质沉积的重要分子,tTG蛋白有望成为预防和治疗后囊膜混浊(posterior capsule opacification, PCO)的新靶点。
Part I Effect of tissue transglutaminase inhibitor on the expression of FN and Col-Ⅳin human lens epithelial cells
Objective To observe the effect of the tissue transglutaminase(tTG) inhibitor monodansyl cadaverineon(MDC) on the expression of fibronectin(FN) and collagenⅣ(Col-Ⅳ) induced by transforming growth factor-β2 (TGF-β2) in human lens epithelial cells (HLECs).
Methods Cultured human lens epithelial cell line(HLE-B3) in vitro were divided into five groups, including:(1)group1, normal control group, (2)group2, 10μg/L TGF-β2-treated group, (3)group3,10μg/L TGF-β2+100μmol/L MDC-treated group, (4)group4,10μg/L TGF-β2+200μmol/L MDC-treated group and (5)group5,10μg/L TGF-β2+400μmol/L MDC-treated group. Semiquantitative RT-PCR was used to assay the expression of tTG, FN and Col-Ⅳin HLE-B3 cells.
Results HLE-B3 cells cultured in vitro expressed certain quantity of tTG, FN and Col-Ⅳ. And the expression of them were markedly increased in group2 as compared with that in group 1 (P<0.01). The expression of FN and Col-Ⅳwere significantly inhibited in group3, 4 and 5 by MDC in a concentration-dependent manner as compared with that in group2(P<0.01).
Conclusion MDC can inhibit the enhanced expression of FN and Col-IV induced by TGF-β2 in HLECs. tTG may be involved in posterior capsule opacification(PCO) through up-regulating the expression of FN and Col-IV in HLECs.
Part II Inhibition of tissue transglutaminase expression in human lens epithelial cells by RNA interference
Objective To investigate the inhibition of tissue transglutaminase (tTG) expression in human lens epithelial cells(HLECs) by RNA interference.
Methods Three specific short interfering RNA (siRNA) of tTG (siRNA-1, siRNA-2, siRNA-3) were designed and synthesized, and transiently transfected into HLE-B3 cells. Real-time RT-PCR and Western blot were used to measure the expression of tTG mRNA and protein respectively.
Results after the transfection with siRNA-1, siRNA-2, siRNA-3 for 48 hours, the tTG mRNA expression were decreased to 46.60%,12.84%and 66.75%of that in blank control group respectively, after the transfection with siRNA-1, siRNA-2, siRNA-3 for 60hours, the tTG protein expression were decreased to 60.49%,27.87%and 55.91%of that in blank control group respectively. All differences had statistical significance (P<0.05～P<0.01). The same result was showed in Real-time RT-PCR and Western blot that siRNA-2 had the best inhibition effect on tTG.
Conclusion siRNA targeting tTG gene is effective in suppressing the tTG expression.
PartⅢThe role of tTG-siRNA in transdifferentiation and extracellular matrix deposition of human lens epithelial cells
Objective To investigate the effect of tissue transglutamiase (tTG) siRNA on transdifferentiation and extracellular matrix deposition of human lens epithelial cells(HLECs) induced by TGF-P2.
Methods Cultured HLE-B3 cells in vitro were divided into normal control group, TGF-P2-group and TGF-β2+siRNA-group. Western blot was used to assay the expression of tTG, a-smooth muscle actin(α-SMA), fibronectin(FN), and collagenⅣ(Col-Ⅳ) in HLE-B3 cells.
Results The expression of tTG,α-SMA, FN and Col-Ⅳwere markedly increased in TGF-P2-group as compared with that in normal control group (P<0.01). And the expression of tTG,α-SMA, FN and Col-Ⅳwere significantly decreased in TGF-P2+siRNA-group as compared with that in TGF-β2-group (P<0.01).
Conclusion siRNA targeting tTG gene can obviously inhibit the synthesis of a-SMA, FN and Col-IV in HLE-B3 cells induced by TGF-β2. It suggests that tTG may play an important role in transdifferentiation and extracellular matrix deposition of HLECs induced by TGF-β2. tTG is hopeful to be a new target for the prevention and treatment of posterior capsule opacification(PCO).
目的观察组织型转谷氨酰胺酶(tissue transglutaminase, tTG)抑制剂单丹磺酰尸胺monodansyl-cadaverine (MDC)对转化生长因子β2 (transforming growth factor-β2, TGF-β2)诱导的人晶状体上皮细胞(Human lens epithelial cells, HLECs)表达纤维连接蛋白(Fibrone-ctin, FN)和Ⅳ型胶原(collagenⅣ, Col-Ⅳ)的影响。
方法将体外培养的人晶状体上皮细胞株HLE-B3分为5组：无血清培养基中培养的HLE-B3为正常对照组；加入10μg/L TGF-β2处理36h的HLE-B3为TGF-p2组;10μg／LTGF-p2与100、200和400μmol/L MDC共同处理36h的HLE-B3为不同浓度MDC组。用半定量RT-PCR检测tTG、FN、Col-Ⅳ在HLE-B3细胞中表达的变化。
结果正常体外培养的HLE-B3细胞中可表达一定量的tTG, FN及Col-Ⅳ。与正常对照组相比,TGF-β2组中tTG, FN和Col-Ⅳ的表达明显增强,差异有统计学意义(P<0.01)。与TGF-β2组相比,100、200和400μmol/L MDC组中FN和Col-Ⅳ的表达含量明显减少(P<0.01)。100、200和400μmol/L MDC组各组间FN和Col-Ⅳ的表达差异亦具有显著性意义(P<0.01)。
结论MDC可剂量依赖性的抑制TGF-p2诱导的LECs中FN和Col-Ⅳ表达的增加。tTG可能通过促进HLECs表达FN和Col-Ⅳ等细胞外基质成分参与白内障术后后囊膜混浊(posterior capsule opacification, PCO)的形成。
第二部分RNA干扰对人晶状体上皮细胞tTG表达的影响研究
目的研究RNA干扰抑制组织型转谷氨酰胺酶(tissue transglutaminase, tTG)对人晶状体上皮细胞(Human lens epithelial cells, HLECs)中tTG表达的影响。
方法设计并合成特异性针对tTG的3对小干扰RNA(short interfering RNA, siRNA): siRNA-1、siRNA-2、siRNA-3,用Real-time RT-PCR和Western blot法检测转染了siRNA后人晶状体上皮细胞株(HLE-B3)中tTG基因在mRNA水平和蛋白水平的变化。
结果转染siRNA-1、siRNA-2、siRNA-348h后,tTG mRNA的表达分别下降为空白对照组的46.60%,12.84%,66.75%,与空白对照组相比差异具有统计学意义(P<0.05)。转染siRNA-1、siRNA-2、siRNA-360h后,tTG蛋白的表达含量分别下降为空白对照组的60.49%,27.87%,55.91%(P<0.01)。Real-time RT-PCR与Western blot检测结果一致显示了siRNA-2对tTG基因的抑制效果最佳。
结论我们设计并合成的靶向tTG的siRNA可以显著降低tTG的表达。
第三部分tTG-siRNA对人晶状体上皮细胞转分化和细胞外基质沉积的作用研究
目的探讨RNA干扰抑制组织型转谷氨酰胺酶(tissue transglutaminase, tTG)的表达对人转化生长因子β2(transforming growth factorβ2, TGF-β2)诱导的人晶状体上皮细胞(Human lens epithelial cells, HLECs)转分化和细胞外基质沉积的抑制作用。
方法将体外培养的人晶状体上皮细胞株HLE-B3分为正常对照组,TGF-β2组和TGF-β2+siRNA组。Western blot法检测各组细胞tTG、α平滑肌肌动蛋白(a-Smooth muscle actin, a-SMA)、纤维连接蛋白(Fibronectin, FN)和Ⅳ型胶原(collagen IV, Col-IV)的表达。
结果与正常对照组相比,TGF-β2组中tTG、α-SMA、FN、Col-Ⅳ的表达量均明显增加(P<0.01)；与TGF-β2组相比,TGF-β2+siRNA组中tTG、α-SMA、FN、Col-Ⅳ的表达量均明显减少(P<0.01)。
结论靶向tTG的siRNA可以明显抑制TGF-β2诱导的HLE-B3细胞合成a-SMA、FN、Col-Ⅳ。提示tTG是介导TGF-β2诱导人晶状体上皮细胞转分化和细胞外基质沉积的重要分子,tTG蛋白有望成为预防和治疗后囊膜混浊(posterior capsule opacification, PCO)的新靶点。
Part I Effect of tissue transglutaminase inhibitor on the expression of FN and Col-Ⅳin human lens epithelial cells
Objective To observe the effect of the tissue transglutaminase(tTG) inhibitor monodansyl cadaverineon(MDC) on the expression of fibronectin(FN) and collagenⅣ(Col-Ⅳ) induced by transforming growth factor-β2 (TGF-β2) in human lens epithelial cells (HLECs).
Methods Cultured human lens epithelial cell line(HLE-B3) in vitro were divided into five groups, including:(1)group1, normal control group, (2)group2, 10μg/L TGF-β2-treated group, (3)group3,10μg/L TGF-β2+100μmol/L MDC-treated group, (4)group4,10μg/L TGF-β2+200μmol/L MDC-treated group and (5)group5,10μg/L TGF-β2+400μmol/L MDC-treated group. Semiquantitative RT-PCR was used to assay the expression of tTG, FN and Col-Ⅳin HLE-B3 cells.
Results HLE-B3 cells cultured in vitro expressed certain quantity of tTG, FN and Col-Ⅳ. And the expression of them were markedly increased in group2 as compared with that in group 1 (P<0.01). The expression of FN and Col-Ⅳwere significantly inhibited in group3, 4 and 5 by MDC in a concentration-dependent manner as compared with that in group2(P<0.01).
Conclusion MDC can inhibit the enhanced expression of FN and Col-IV induced by TGF-β2 in HLECs. tTG may be involved in posterior capsule opacification(PCO) through up-regulating the expression of FN and Col-IV in HLECs.
Part II Inhibition of tissue transglutaminase expression in human lens epithelial cells by RNA interference
Objective To investigate the inhibition of tissue transglutaminase (tTG) expression in human lens epithelial cells(HLECs) by RNA interference.
Methods Three specific short interfering RNA (siRNA) of tTG (siRNA-1, siRNA-2, siRNA-3) were designed and synthesized, and transiently transfected into HLE-B3 cells. Real-time RT-PCR and Western blot were used to measure the expression of tTG mRNA and protein respectively.
Results after the transfection with siRNA-1, siRNA-2, siRNA-3 for 48 hours, the tTG mRNA expression were decreased to 46.60%,12.84%and 66.75%of that in blank control group respectively, after the transfection with siRNA-1, siRNA-2, siRNA-3 for 60hours, the tTG protein expression were decreased to 60.49%,27.87%and 55.91%of that in blank control group respectively. All differences had statistical significance (P<0.05～P<0.01). The same result was showed in Real-time RT-PCR and Western blot that siRNA-2 had the best inhibition effect on tTG.
Conclusion siRNA targeting tTG gene is effective in suppressing the tTG expression.
PartⅢThe role of tTG-siRNA in transdifferentiation and extracellular matrix deposition of human lens epithelial cells
Objective To investigate the effect of tissue transglutamiase (tTG) siRNA on transdifferentiation and extracellular matrix deposition of human lens epithelial cells(HLECs) induced by TGF-P2.
Methods Cultured HLE-B3 cells in vitro were divided into normal control group, TGF-P2-group and TGF-β2+siRNA-group. Western blot was used to assay the expression of tTG, a-smooth muscle actin(α-SMA), fibronectin(FN), and collagenⅣ(Col-Ⅳ) in HLE-B3 cells.
Results The expression of tTG,α-SMA, FN and Col-Ⅳwere markedly increased in TGF-P2-group as compared with that in normal control group (P<0.01). And the expression of tTG,α-SMA, FN and Col-Ⅳwere significantly decreased in TGF-P2+siRNA-group as compared with that in TGF-β2-group (P<0.01).
Conclusion siRNA targeting tTG gene can obviously inhibit the synthesis of a-SMA, FN and Col-IV in HLE-B3 cells induced by TGF-β2. It suggests that tTG may play an important role in transdifferentiation and extracellular matrix deposition of HLECs induced by TGF-β2. tTG is hopeful to be a new target for the prevention and treatment of posterior capsule opacification(PCO).
引文
1. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification [J]. Surv Ophthalmol,1992,37:73-116.
2. Pandey SK, Wilson ME, Trivedi RH, et al. Pediatric cataract surgery and intraocular lens implantation:current techniques, complications and management [J]. Int Ophthalmol Clin,2001,41(3):175-196.
3. Pandey SK, Wilson ME, Trivedi RH, et al. Pediatric cataract surgery and intraocular lens implantation:current technigues, complications, and management [J]. Int Ophthalmol Clin,2001,41(3):175-196.
4. Shaumberg DA, Dana MR, Christen WG, et al. A systemic overview of the incidence of posterior capsular opacification [J]. Ophthalmology,1998,105:1213-1221.
5. Pandey SK, Apple DJ, Werner L, et al. Posterior capsule opacification:a review of the aetiopathogenesis, experimental and clinical studies and factors for prevention [J]. Indian J Ophthalmol,2004,52(2):99-112.
6. HansenTJ, TyndallR, SoilDB. Methotrexate-anticolagen conjugate inhibits in vitro lens cell outgrouth [J]. Invest Ophthalmol Vis Sci,1987,28:1206
7. Mansfield KJ, Cerra A, Chamberlain CG. Effects of dexamethasone on posterior capsule opacification-like changes in a rat lens explant model [J]. Mol Vis,2004, 6(10):728-737.
8. Yoshitomi F, Utsumi E, Hayashi M, et al. Postoperative fluctuations of tissue plasminogen activator (t-PA)in aqueous humor of pseudophakes [J]. J Cataract Refract Surg,1991,5:543-546.
9. Mattern RM, Zuk A, Hay ED. Retinoic acid inhibits formation of mesenchyme from lens epithelium in collagen gels [J]. Invest Ophthalmol Vis Sci,1993,34(8): 2526-2537.
10. Lee EH, Joo CK. Role of transforming growth factor-beta in transdifferentiaion and fibrosis of lens epithelial cells [J]. Invest Ophthalmol Vis Sci,1999,40:2025-2032.
11. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. 2002; 43(7):2301-2308.
12. Liu J, Hales AM, Chamberlain CG, McAvoy JW. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci,1994,35:388-401.
13. Roberts AB. Molecular and cell biology of TGF-beta [J]. Miner Electrolyte Metab, 1998,24(2-3):111-119.
14. Saika S, Saika S, Liu CY, et al. TGF-beta2 in corneal morphogenesis during mouse embryonic development [J]. Dev Biol,2001,240(2):419-432.
15. Dunker N, Krieglstein K. Reduced programmed cell death in the retina and defects in lens and cornea of Tgf beta2(-/-) Tgf beta3(-/-) double-deficient mice [J]. Cell Tissue Res,2003,313(1):1-10.
16. Borsook H, Deasy CL, Haagen-Smit AJ, et al. The incorporation of labeled lysine into the proteins of guinea pig liver homogenate [J]. J Biol Chem,1949,179:689-704.
17. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
18. Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases [J]. Front Biosci,2006,11:1758-1773.
19. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
20. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
21. Upchurch HF, Conway E, Patterson MK Jr, et al. Localization of cellular transglutaminase on the extracellular matrix after wounding:characteristics of the matrix bound enzyme [J]. J Cell Physiol,1991,149(3):375-382.
22. Akimov SS, Belkin AM. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin [J]. Blood,2001,98(5):1567-1576.
23. Schnabel C, Sawitza I, Tag C G, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28:140-145.
24. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
25. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages [J]. J Immunol,1995,155(3):1450-1459.
26. Shweke N, Boulos N, Jouanneau C, et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration [J]. Am J Pathol,2008,173(3):631-642.
27. Shin DM, Jeon JH, Kim CW, et al. TGF-beta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation [J]. FASEB J,2008, 22(7):2498-2507.
28. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation. Proc Natl Acad Sci USA.1981,78(3):1356-1360.
29. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
30. Shridas P, Sharma Y, Balasubramanian D, et al. Transglutaminase-mediated cross-linking of alpha-crystallin:structural and functional consequences [J]. FEBS Lett,2001,499(3):245-250.
31. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in anterior polar cataracts and its induction by TGF-P in vitro [J]. Br J Ophthalmol,2002,86: 1293-1298.
1. Spalton D J. Posterior capsular opacification after cataract surgery [J]. Eye,1999,13: 489-492.
2. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005,179(1-2):43-55.
3. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification [J]. Exp Eye Res, 2009,88(2):257-269.
4. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994,71(4):402-415.
5. Zemskov EA, Janiak A. Hang J, Waghray A, et al. The role of tissue transglutaminase in cell-matrix interactions [J]. Front Biosci,2006,11:173-185.
6.李凤鸣.眼科全书(第1版)[M].北京：人民卫生出版社,1996,1577-1597.
7. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification [J]. Surv Ophthalmol,1992,37:73.
8. Bertelmann E, Kojetinsky C. Posterior capsule opacification and anterior capsule opacification [J]. Curr Opin Ophthalmol,2001,12(1):35-40.
9. Marcantonio JM, Vrensen GF. Cell biology of posterior capsular opacification [J]. Eye, 1999,13:484-488.
10. Srinivasan Y, Lovicu FJ, Overbeek PA. Lens-specific expression of transforming growth factor betal in transgenic mice causes anterior subcapsular cataracts [J]. J Clin Invest,1998,101:625-34.
11. Lovicu FJ, Schulz MW, Hales AM, et al. TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract [J]. Br J Ophthalmol,2002, 86(2):220-226.
12. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36:1709-1713.
13. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis
Sci,2002,43(7):2301-2308.
14. Folk JE. Transglutaminases [J]. Annu Rev Biochem,1980,49:517-531.
15. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
16. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
17. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response [J]. Amino Acids,2007,33(2):385-394.
18. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation. Proc Natl Acad SciU S A,1981,78(3):1356-1360.
19. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
20. Shridas P, Sharma Y, Balasubramanian D, et al. Transglutaminase-mediated cross-linking of alpha-crystallin:structural and functional consequences [J]. FEBS Lett,2001,499(3):245-250.
21. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in anterior polar cataracts and its induction by TGF-β in vitro [J]. Br J Ophthalmol,2002,86: 1293-1298.
22. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
23. Upchurch HF, Conway E, Patterson MKJ, et al. Localization of cellular transglutaminase on the extracellular matrix after wounding:characteristics of the matrix bound enzyme [J]. J Cell Physiol,1991,149:375-382.
24. Clement S, Velasco PT, Murthy SN, et al. The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase [J]. J Biol Chem,1998, 273(13):7604-7609.
25. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures [J]. Invest Ophthalmol Vis Sci, 1999,40(12):2780-2787.
26. Olivero DK, Furcht LT. Type IVcollagen, laminin and fibronectin promote the adhesion and migration of rabbit lens epithelial cells in vitro [J]. Invest Ophthalmol Vis Sci,1993, 34(10):2825-2834.
27. Futter CE, Crowston JG, Allan BD. Interaction with collagen IV protects lens epithelial cells from Fas-dependent apoptosis by stimulating the production of soluble survival factors [J]. Invest Ophthalmol Vis Sci.2005,46(9):3256-3262.
28. Parmigani CM, Mcavoy J W. The roles of laminin and fibronectin in the development of the lens capsule [J]. Curr Eve Res,1991,10(6):501-511.
29. Nishimoto H. Morphological study of the cataractous lens of the senescence accelerated mouse [J]. Grafe's Arch Clin Exp Ophthalmol,1993,231(1):722-726.
30. Oharazaw H, Ibaraki N, Lin LR, et al. The effects of extracellular matrix on cell attachment, proliferation and migration in a human lens epithelial cell line [J]. Exp Eye Res,1999,69(6):603-610.
31. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
32. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin:a role in TGFβ-dependent matrix deposition [J]. J Cell Sci,2001,114(16):2989-3000.
33. Akimov SS, KrylovD, Fleischman LF, et al. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin [J]. J Cell Biol,2000,148:825-838.
34. Wederell ED, de Iongh RU. Extracellular matrix and integrin signaling in lens development and cataract [J]. Semin Cell Dev Biol,2006,17(6):759-776.
35. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
1. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994; 71(4):402-415.
2. Fire A, Xu S, Monotgomery MK, et al. Potent and specific genetic interference by double-strand RNA in Caenorhabditis elegans [J]. Nature,1998,391(6669):806-811.
3. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J]. Nature,2001,411(6836):494-498.
4. Agami R. RNAi and related mechanisms and their potential use for therapy [J]. Curr Opin Chem Biol,2002,6(6):829-834.
5. Carthew RW. Gene silencing by double-stranded RNA [J]. Curr Opin Cell Biol,2001, 13(2):244-248.
6. Tijsterman M, Plasterk RH. Dicers at RISC:the mechanism of RNAi [J]. Cell,2004, 117(1):1-3.
7. Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells [J]. Ann N Y Acad Sci,2003,1002:56-62.
8. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects [J]. EMBO MolMed,2009,1(3):142-151.
9. Dorsett Y, Tuschl T. siRNAs:applications in functional genomics and potential as therapeutics [J]. Nat Rev Drug Discov,2004,3(4):318-329.
10. Lykke-Andersen K. Regulation of gene expression in mouse embryos and its embryonic cells through RNAi. Mol Biotechnol [J].2006,34(2):271-278.
11. Orlacchio A, Bernardi G, Orlacchio A, et al. RNA interference as a tool for Alzheimer's disease therapy [J]. Mini Rev Med Chem,2007,7(11):1166-1176.
12. Dykxhoorn DM. RNA interference as an anticancer therapy:a patent perspective [J]. Expert Opin Ther Pat,2009,19(4):475-491.
13. Janoria KG, Gunda S, Boddu SH, et al. Novel approaches to retinal drug delivery [J]. Expert Opin Drug Deliv,2007,4(4):371-388.
14. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease [J]. Expert Opin Investig Drugs,2009 Oct,18(10): 1505-1517.
15. Wu CJ, Chan YL. Antiviral applications of RNAi for coronavirus [J]. Expert Opin Investig Drugs,2006,15(2):89-97.
16. Pruijn GJ. The RNA interference pathway:a new target for autoimmunity [J]. Arthritis ResTher,2006,8(4):110.
17. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs [J]. Nat Rev Genet,2002,3(10):737-747.
18. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
19. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
1. Spalton D J. Posterior capsular opacification after cataract surgery [J]. Eye,1999; 13: 489-492.
2. Lois N, Taylor J, McKinnon AD, et al. Effect of TGF-beta2 and anti-TGF-beta2 antibody in a new in vivo rodent model of posterior capsule opacification [J]. Invest Ophthalmol Vis Sci,2005,46(11):4260-4266.
3. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification [J]. Exp Eye Res, 2009,88(2):257-269.
4. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994; 71(4):402-415.
5. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005; 179(1-2):43-55.
6. Shigemitsu T, Ishiguro K, Shimizu Y, et al. Immunocytochemical features of lens after cataract tissue-signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins [J]. Int Ophthalmol,1999,23(3):137-144.
7. Kurosaka D, Kato K, Nagamoto T, et al. Growth factors influence contractility and alpha-smooth muscle actin expression in bovine lens epithelial cells [J]. Invest Ophthalmol Vis Sci,1995,36(8):1701-1708.
8. Wang XL, Zhang JS, Yu T. Laminin and fibronectin influence growth characteristics of human lens epithelial cells in vitro [J]. Zhonghua Yan Ke Za Zhi,2005,41(4): 340-345.
9. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
10. Liu J, Hales AM, Chamberlain CG, et al. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci, 1994,35(2):388-401.
11. Gordon-Thomson C, de Iongh RU, Hales AM, et al. Differential cataractogenic potency of TGF-betal,-beta2, and-beta3 and their expression in the postnatal rat eye [J]. Invest Ophthalmol Vis Sci,1998,39(8):1399-1409.
12. Lovicu FJ, Schulz MW, Hales AM, et al. TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract [J]. Br J Ophthalmol, 2002,86(2):220-226.
13. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36:1709-1713.
14. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis Sci.2002; 43(7):2301-2308.
15. Schnabel C, Sawitza I, Tag C G, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28:140-145.
16. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-betal mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J]. Mol Biol Cell 2001,12:27-36.
17. Cho HJ, Yoo J. Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells [J]. Cell Biol Int,2007, 31(10):1225-1230.
18. Wittinghofer F. Ras signaling. Caught in the act of the switch-on [J]. Nature,1998,394: 317-320.
19. Masszi A, Diciano C, Sirokmany G, et al. Central role for Rho in TGF-betal-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition [J]. Am J Physiol Renal Physiol,2003,284:911-924.
20. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase Ⅱ in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
21. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes Rho A activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway [J]. Mol Biol Cell,2006,17(4):1606-1619.
22. Olivero DK, Furcht LT. Type IV collagen, laminin, and fibronectin promote the adhesion and migration of rabbit lens epithelial cells in vitro [J]. Invest Ophthalmol Vis Sci,1993,34(10):2825-2834.
23. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J]. Nature,2001,411:494-498.
24. Dorsett Y, Tuschl T. siRNAs:applications in functional genomics and potential as therapeutics [J]. Nat Rev Drug Discov,2004,3(4):318-329.
25.陈春林.RNA干扰技术及其在眼科疾病中的应用[J].眼科新进展,2008,28(1)：60-64.
1. Clarke DD, Mycek MJ, Neidle A, et al. The Incorporation of Amines into Protein [J]. Arch BiochemBiophys,1959,79:338-354.
2. Lorand L, Graham RM. Transglutaminases:crosslinking enzymes with pleiotropic functions [J]. Nat Rev Mol Cell Biol,2003,4(2):140-156.
3. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
4. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications [J]. Amino Acids,2009,36(4): 659-670.
5. Mhaouty-Kodja S. Ghalpha/tissue transglutaminase 2:an emerging G protein in signal transduction [J]. Biol Cell,2004,96(5):363-367.
6. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival [J]. FEBS Lett,2005,579(15):3297-3302.
7. Kim SY. Transglutaminase 2 in inflammation [J]. Front Biosci,2006,11:3026-3035.
8. Elli L, Bergamini CM, Bardella MT, et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver [J]. Dig Liver Dis,2009,41(8): 541-550.
9. Hoffner G, Djian P. Transglutaminase and diseases of the central nervous system [J]. Front Biosci,2005,10:3078-3092.
10. Molberg O, McAdam SN, Sollid LM. Role of tissue transglutaminase in celiac disease [J]. J Pediatr Gastroenterol Nutr,2000,30(3):232-240.
11. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases [J]. Front Biosci,2007,12:2530-2545.
12. Mangala LS, Mehta K. Tissue transglutaminase(TG2) in cancer biology [J]. Prog Exp Tumor Res,2005,38:125-138.
13. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
14. Tovar-Vidales T, Roque R, Clark AF, et al. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues [J]. Invest Ophthalmol Vis Sci,2008,49(2):622-628.
15. Priglinger SG, May CA, Neubauer AS, et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes [J]. Invest Ophthalmol Vis Sci, 2003,44(1):355-364.
16. Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity [J]. Proc Natl Acad Sci,2002,99(5):2743-2747.
17. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases:multifunctional cross-linking enzymes that stabilize tissues [J]. FASEB J,1991,5(15):3071-3077.
18. Samuelsson B, Stenberg P, Pandolfi M. Localization and characteristics of transglutaminase in the rabbit and human eye [J]. Graefes Arch Clin Exp Ophthalmol, 1982,218(5):233-236.
19. Chen JSK, Mehta K. Tissue transglutaminase:an enzyme with a split personality [J]. Int JBiochem Cell Biol,1999,31(8):817-836.
20. Hang J, Zemskov EA, Lorand L, et al. Identifiction of a Novel Recognition Sequence for Fibronectin within the NH2-terminal β-Sandwich Domain of Tissue Transglutaminase [J]. J Biol Chem,2005,280(25):23675-23683.
21. Verderio E, Nicholas B, Gross S, et al. Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts:effects on the processing of fibronectin, cell attachment, and cell death [J]. Exp Cell Res,1998,239(1):119-138.
22. Folk JE. Transglutaminases [J]. Annu Rev Biochem,1980,49:517-531.
23. Lee KN, Arnold SA, Birckbichler PJ, et al. Site-directed mutagenesis of human tissue transglutaminase:Cys-277 is essential for transglutaminase activity but not for GTPase activity [J]. Biochim Biophys Acta,1993,1202(1):1-6.
24. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
25. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
26. Verma A, Mehta K. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells:a new therapeutic opportunity [J]. Curr Cancer Drug Targets,2007,7(6):559-565.
27. Peng X, Zhang Y, Zhang H, et al. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3 [J]. FEBS Lett,1999,446(1):35-39.
28. Kim JH, Nam KH, Kwon OS, et al. Histone cross-linking by transglutaminase [J]. Biochem Biophys Res Commun,2002,293(5):1453-1457.
29. Casadio R, Polverini E, Mariani P, et al. The structural basis for the regulation of tissue transglutaminase by calcium ions [J]. Eur J Biochem,1999,262(3):672-679.
30. Jeon JH, Cho SY, Kim CW, et al. GTP is required to stabilize and display transamidation activity of transglutaminase 2 [J]. Biochem Biophys Res Commun, 2002,294(4):818-822.
31. Chen S, Lin F, Iismaa S, et al. Alphal-adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity. J Biol Chem,1996,271(50): 32385-32391.
32. Goodhardt M, Ferry N, Aggerbeck M, et al. The hepatic alpha 1-adrenergic receptor [J]. Biochem Pharmacol,1984,33(6):863-868.
33. Nakaoka H, Perez DM, Baek KJ, et al. Gh:a GTP-binding protein with transglutaminase activity and receptor signaling function [J]. Science,1994, 264(5165):1593-1596.
34. Stephens P, Grenard P, Aeschlimann P, et al.Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses [J]. J Cell Sci,2004,117(15):3389-3403.
35. O'toole TE, Katagiri Y, Faull RJ, et al. Integrin cytoplasmic domains mediate inside-out signal transduction[J]. JCellBiol,1994,124(6):1047-1059.
36. Ekblom P, Timpl R. Cell-to-cell contact and extracellular matrix. A multifaceted approach emerging [J]. Curt Opin Cell Biol,1996,8(5):599-601.
37. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp:a versatile cell recognition signal [J]. Cell,1986,44(4):517-518.
38. Bloor DJ, Metcalfe AD, Rutherford A, et al. Expression of cell adhesion molecules during human preimplantation embryo development [J]. Mol Hum Reprod,2002,8(3): 237-245.
39. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion [J]. Curr Opin Cell Biol,2007,19(5):495-507.
40. Moissoglu K, Schwartz MA. Integrin signalling in directed cell migration [J]. Biol Cell, 2006,98(9):547-555.
41. Dean DC, Iademarco MF, Rosen GD, et al. The integrin alpha 4 beta 1 and its counter receptor VCAM-1 in development and immune function [J]. Am Rev Respir Dis,1993, 148:43-46.
42. Grinnell F. Wound repair, keratinocyte activation and integrin modulation [J]. J Cell Sci, 1992,101(1):1-5.
43. Akimov, SS, Krylov D, Fleischman, LF. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin [J]. Cell Biol,2000,148,825-838.
44. Sechler JL, Schwarzbauer JE. Control of cell cycle progression by fibronectin matrix architecture [J]. J Biol Chem,1998,273(40):25533-25536.
45. Hadden HL, Henke CA. Induction of lung fibroblast apoptosis by soluble fibronectin peptides [J]. Am J Respir Crit Care Med,2000,162:1553-1560.
46. Jeong J, Han I, Lim Y, et al. Rat embryo fibroblasts require both the cell-binding and the heparin-binding domains of fibronectin for survival [J]. Biochem J,2001,356(2): 531-537.
47. Sharma A, Askari JA, Humphries MJ, et al. Crystal structure of a heparin-and integrin-binding segment of human fibronectin [J]. EMBO J,1999,18(6):1468-1479.
48. Zemskov EA, Janiak A, Hang J, et al. The role of tissue transglutaminase in cellmatrix interactions [J]. Front Biosci,2006,11:173-185.
49. Takahashi H, Isobe T, Horibe S, et al. Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1 [J]. J Biol Chem,2000,275(31):23589-23595.
50. Balklava Z, Verderio E, Collighan R, et al. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts [J]. Biol Chem,2002,277:16567-16575.
51. Verderio EA, Telci D, Okoye A, et al. A novel RGD-independent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis [J]. J Biol Chem,2003,278(43):42604-42614.
52. Burridge K, Wennerberg K. Rho and Rac take center stage [J]. Cell,2004,116(2): 167-179.
53. Wittinghofer F. Ras signaling. Caught in the act of the switch-on [J]. Nature,1998,394: 317-320.
54. Loirand G, Guerin P, Pacaud P, et al. Rho kinases in cardiovascular physiology and pathophysiology [J]. Circ Res,2006,98(3):322-334.
55. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [J]. Science,1996,273 (5272):245-248.
56. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
57. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway [J]. Mol Biol Cell,2006,17(4):1606-1619.
58. Redding GS, Record DM, Raess BU. Calcium-stressed erythrocyte membrane structure and function for assessing glipizide effects on transglutaminase activation [J]. Proc Soc Exp Biol Med,1991,196(1):76-82.
59. Telci D, Collighan RJ, Basaga H, et al. Increased TG2 expression can result in induction of transforming growth factor betal, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide [J]. J Biol Chem, 2009,284(43):29547-29558.
60. Monsonego A, Friedmann I, Shani Y, et al.GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase [J]. J Mol Biol,1998,282(4):713-720.
61. Lee SC, Kim JH, Park ES, et al. Ca2+:a stabilizing component of the transglutaminase activity of Galphah (transglutaminase II). Mol Cells,2003,16(3):285-290.
62. Ishii I, Ui M. Retinoic acid-induced gene expression of tissue transglutaminase via protein kinase C-dependent pathway in mouse peritoneal macrophages [J]. J Biochem, 1994,115(6):1197-1202.
63. Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB [J]. Am J Physiol,1997,272:281-288.
64. Jung SA, Lee HK, Yoon JS, et al. Upregulation of TGF-beta-induced tissue transglutaminase expression by PI3K-Akt pathway activation in human subconjunctival fibroblasts [J]. Invest Ophthalmol Vis Sci,2007,48(5):1952-1958.
65. Kuncio GS, Tsyganskaya M, Zhu J, et al. TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells [J]. Am J Physiol,1998,274:240-245.
66. Johnson K, Hashimoto S, Lotz M, et al. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor ⅩⅢa [J]. Am J Pathol,2001,159(1): 149-163.
67. Ikura K, Shinagawa R, Suto N, et al. Increase caused by interleukin-6 in promoter activity of guinea pig liver transglutaminase gene [J]. Biosci Biotechnol Biochem, 1994,58(8):1540-1541.
68. Fraij BM, Gonzales RA. Organization and structure of the human tissue transglutaminase gene [J]. Biochim Biophys Acta,1997,1354(1):65-71.
69. Lu S, Saydak M, Gentile V, et al. Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem.1995,270(17):9748-9756.
70. Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer [J]. Carcinogenesis,2008,29(3):510-518.
71. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response [J]. Amino Acids,2007,33(2):385-394.
72. Medina MA. Glutamine and cancer [J]. J Nutr,2001,131:2539-2542.
73. Autuori F, Farrace MG, Oliverio S, et al. "Tissue" transglutaminase and apoptosis [J]. Adv Biochem Eng Biotechnol,1998,62:129-136.
74. Rodolfo C, Mormone E, Matarrese P, et al. Tissue transglutaminase is a multifunctional BH3-only protein [J]. J Biol Chem,2004,279(52):54783-54792.
75. Robitaille K, Daviau A, Lachance G, et al. Calphostin C-induced apoptosis is mediated by a tissue transglutaminase-dependent mechanism involving the DLK/JNK signaling pathway [J]. Cell Death Differ,2008,15(9):1522-1531.
76. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis:evidence for incomplete resolution associated with matrix cross-linking [J]. Gastroenterology,2004,126:1795-1808.
77. Hwang JY, Mangala LS, Fok JY, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma [J]. Cancer Res,2008,68(14):5849-5858.
78. Kim DS, Park KS, Kim SY. Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors [J]. Front Biosci,2009,14:2514-2521.
79. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells [J]. Drug Resist Updat,2007,10(4-5):144-151.
80. Yamaguchi H, Wang HG. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells [J]. Mol Cell Biol,2006, 26(2):569-579.
81. Clement S, Velasco PT, Murthy SN, et al. The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase [J]. J Biol Chem,1998, 273(13):7604-7609.
82. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures [J]. Invest Ophthalmol Vis Sci,1999,40(12):2780-2787.
83. Roberts AB. Molecular and cell biology of TGF-beta [J]. Miner Electrolyte Metab, 1998,24(2-3):111-119.
84. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
85. Antonyak MA, Li B, Regan AD, et al. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem.2009,284(27):17914-17925.
86. Stephens P, Grenard P, Aeschlimann P, et al. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses [J]. J Cell Sci,2004,117(15):3389-3403.
87. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [J]. Science,1996,273(5272):245-248.
88. Kalluri R. EMT:when epithelial cells decide to become mesenchymal-like cells [J]. J Clin Invest,2009,119(6):1417-1419.
89. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer:do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem,2007,101(4):830-839.
90. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-betal mediates epithelial to mesenchymal-transdifferentiation through a RhoA-dependent mechanism [J]. Mol Biol Cell,2001,12:27-36.
91. Patel S, Takagi KI, Suzuki J, et al. RhoGTPase Activation Is a Key Step in Renal Epithelial Mesenchymal Transdifferentiation. [J]. Am Soc Nephrol 2005,16(7): 1977-1984.
92. Schnabel C, Sawitza I, Tag CG, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28: 140-145.
93. Shao M, Cao L, Shen C, et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase [J]. Cancer Res,2009,69(24): 9192-9201.
94. Burton M, Fergusson E, Hart A, et al. The prevalence of cataract in two villages of northern Pakistan with different levels of ultraviolet radiation [J]. Eye (Lond),1997, 11(1):95-101.
95. Duncan G, Jacob TJ. Calcium and the physiology of cataract [J]. Ciba Found Symp, 1984,106:132-152.
96. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation [J]. Proc Natl Acad Sci USA,1981,78(3):1356-1360.
97. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
98. Velasco PT, Murthy P, Goll DE, et al. Cross-linking and proteolysis in Ca2(+)-treated lens homogenates [J]. Biochim Biophys Acta,1990,1040(2):187-191.
99. Andley UP. Effects of alpha-crystallin on lens cell function and cataract pathology [J]. Curr Mol Med,2009,9(7):887-892.
100. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005; 179(1-2):43-55.
101. Parmigani CM, Mcavoy J W. The roles of laminin and fibronectin in the development of the lens capsule [J]. Curr Eve Res,1991,10(6):501-511.
102. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
103. Liu J, Hales AM, Chamberlain CG, et al. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci, 1994,35(2):388-401.
104. Gordon-Thomson C, de Iongh RU, Hales AM, et al. Differential cataractogenic potency of TGF-betal,-beta2, and-beta3 and their expression in the postnatal rat eye [J]. Invest Ophthalmol Vis Sci,1998,39(8):1399-1409.
105. Hales AM, Chamberlain CG, McAvoy JW, et al. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36: 1709-1713.
106. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis Sci.2002; 43(7):2301-2308.
107. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in
anterior polar cataracts and its induction by TGF-β in vitro [J]. Br J Ophthalmol,2002, 86:1293-1298.
108. Knepper PA, Goossens W, Palm berg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma [J]. Invest Ophthalmol Vis Sci, 1996,37(5):1360-1367.
109. Tovar-Vidales T, Roque R, Clark AF, et al. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues [J]. Invest Ophthalmol Vis Sci,2008,49(2):622-628.
110. Stefan C, Dragomir L, Dumitrica DM, et al. TGF-beta2 involvements in open angle glaucoma. Oftalmologia,2008,52(3):110-112.
111. Priglinger SG, Alge CS, Kook D, et al. Potential role of tissue transglutaminase in glaucoma filtering surgery [J]. Invest Ophthalmol Vis Sci,2006,47(9):3835-3845.
112. Hiscott P, Sheridan C, Magee RM, et al. Matrix and the retinal pigment epithelium in proliferative retinal disease [J]. Prog Retin Eye Res,1999,18(2):167-190.
113. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye [J]. J Clin Invest,1989,83(5):1661-1666.
114.王辉,刘哲丽,郝旭红等.增生性玻璃体视网膜病变中组织型转谷氨酰胺酶的表达[J].国际眼科杂志,2007,2(7)：392-394.
115. Priglinger SG, May CA, Neubauer AS, et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes [J]. Invest Ophthalmol Vis Sci, 2003,44(1):355-364.
116. Priglinger SG, Alge CS, Neubauer AS, et al. TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain [J]. Invest Ophthalmol Vis Sci,2004,45(3): 955-963.
117. Tamai M. Progress in pathogenesis and therapeutic research in retinitis pigmentosa and age-related macular degeneration. Nippon Ganka Gakkai Zasshi,2004,108(12):
750-768.
118. Zhang SR, Li SH,Abler A, et al. Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina [J]. Invest Ophthalmol Vis Sci,1996,37:1793-1799.
119. Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases:from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes [J]. Hum Mol Genet,2002,11(20):2371-2375.
120. Sohn J, Chae JB, Lee SY, et al. A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor [J]. Korean J Ophthalmol,2010,24(1):29-34.
2. Pandey SK, Wilson ME, Trivedi RH, et al. Pediatric cataract surgery and intraocular lens implantation:current techniques, complications and management [J]. Int Ophthalmol Clin,2001,41(3):175-196.
3. Pandey SK, Wilson ME, Trivedi RH, et al. Pediatric cataract surgery and intraocular lens implantation:current technigues, complications, and management [J]. Int Ophthalmol Clin,2001,41(3):175-196.
4. Shaumberg DA, Dana MR, Christen WG, et al. A systemic overview of the incidence of posterior capsular opacification [J]. Ophthalmology,1998,105:1213-1221.
5. Pandey SK, Apple DJ, Werner L, et al. Posterior capsule opacification:a review of the aetiopathogenesis, experimental and clinical studies and factors for prevention [J]. Indian J Ophthalmol,2004,52(2):99-112.
6. HansenTJ, TyndallR, SoilDB. Methotrexate-anticolagen conjugate inhibits in vitro lens cell outgrouth [J]. Invest Ophthalmol Vis Sci,1987,28:1206
7. Mansfield KJ, Cerra A, Chamberlain CG. Effects of dexamethasone on posterior capsule opacification-like changes in a rat lens explant model [J]. Mol Vis,2004, 6(10):728-737.
8. Yoshitomi F, Utsumi E, Hayashi M, et al. Postoperative fluctuations of tissue plasminogen activator (t-PA)in aqueous humor of pseudophakes [J]. J Cataract Refract Surg,1991,5:543-546.
9. Mattern RM, Zuk A, Hay ED. Retinoic acid inhibits formation of mesenchyme from lens epithelium in collagen gels [J]. Invest Ophthalmol Vis Sci,1993,34(8): 2526-2537.
10. Lee EH, Joo CK. Role of transforming growth factor-beta in transdifferentiaion and fibrosis of lens epithelial cells [J]. Invest Ophthalmol Vis Sci,1999,40:2025-2032.
11. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci. 2002; 43(7):2301-2308.
12. Liu J, Hales AM, Chamberlain CG, McAvoy JW. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci,1994,35:388-401.
13. Roberts AB. Molecular and cell biology of TGF-beta [J]. Miner Electrolyte Metab, 1998,24(2-3):111-119.
14. Saika S, Saika S, Liu CY, et al. TGF-beta2 in corneal morphogenesis during mouse embryonic development [J]. Dev Biol,2001,240(2):419-432.
15. Dunker N, Krieglstein K. Reduced programmed cell death in the retina and defects in lens and cornea of Tgf beta2(-/-) Tgf beta3(-/-) double-deficient mice [J]. Cell Tissue Res,2003,313(1):1-10.
16. Borsook H, Deasy CL, Haagen-Smit AJ, et al. The incorporation of labeled lysine into the proteins of guinea pig liver homogenate [J]. J Biol Chem,1949,179:689-704.
17. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
18. Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases [J]. Front Biosci,2006,11:1758-1773.
19. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
20. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
21. Upchurch HF, Conway E, Patterson MK Jr, et al. Localization of cellular transglutaminase on the extracellular matrix after wounding:characteristics of the matrix bound enzyme [J]. J Cell Physiol,1991,149(3):375-382.
22. Akimov SS, Belkin AM. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin [J]. Blood,2001,98(5):1567-1576.
23. Schnabel C, Sawitza I, Tag C G, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28:140-145.
24. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
25. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages [J]. J Immunol,1995,155(3):1450-1459.
26. Shweke N, Boulos N, Jouanneau C, et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration [J]. Am J Pathol,2008,173(3):631-642.
27. Shin DM, Jeon JH, Kim CW, et al. TGF-beta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation [J]. FASEB J,2008, 22(7):2498-2507.
28. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation. Proc Natl Acad Sci USA.1981,78(3):1356-1360.
29. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
30. Shridas P, Sharma Y, Balasubramanian D, et al. Transglutaminase-mediated cross-linking of alpha-crystallin:structural and functional consequences [J]. FEBS Lett,2001,499(3):245-250.
31. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in anterior polar cataracts and its induction by TGF-P in vitro [J]. Br J Ophthalmol,2002,86: 1293-1298.
1. Spalton D J. Posterior capsular opacification after cataract surgery [J]. Eye,1999,13: 489-492.
2. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005,179(1-2):43-55.
3. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification [J]. Exp Eye Res, 2009,88(2):257-269.
4. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994,71(4):402-415.
5. Zemskov EA, Janiak A. Hang J, Waghray A, et al. The role of tissue transglutaminase in cell-matrix interactions [J]. Front Biosci,2006,11:173-185.
6.李凤鸣.眼科全书(第1版)[M].北京：人民卫生出版社,1996,1577-1597.
7. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification [J]. Surv Ophthalmol,1992,37:73.
8. Bertelmann E, Kojetinsky C. Posterior capsule opacification and anterior capsule opacification [J]. Curr Opin Ophthalmol,2001,12(1):35-40.
9. Marcantonio JM, Vrensen GF. Cell biology of posterior capsular opacification [J]. Eye, 1999,13:484-488.
10. Srinivasan Y, Lovicu FJ, Overbeek PA. Lens-specific expression of transforming growth factor betal in transgenic mice causes anterior subcapsular cataracts [J]. J Clin Invest,1998,101:625-34.
11. Lovicu FJ, Schulz MW, Hales AM, et al. TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract [J]. Br J Ophthalmol,2002, 86(2):220-226.
12. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36:1709-1713.
13. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis
Sci,2002,43(7):2301-2308.
14. Folk JE. Transglutaminases [J]. Annu Rev Biochem,1980,49:517-531.
15. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
16. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
17. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response [J]. Amino Acids,2007,33(2):385-394.
18. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation. Proc Natl Acad SciU S A,1981,78(3):1356-1360.
19. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
20. Shridas P, Sharma Y, Balasubramanian D, et al. Transglutaminase-mediated cross-linking of alpha-crystallin:structural and functional consequences [J]. FEBS Lett,2001,499(3):245-250.
21. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in anterior polar cataracts and its induction by TGF-β in vitro [J]. Br J Ophthalmol,2002,86: 1293-1298.
22. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
23. Upchurch HF, Conway E, Patterson MKJ, et al. Localization of cellular transglutaminase on the extracellular matrix after wounding:characteristics of the matrix bound enzyme [J]. J Cell Physiol,1991,149:375-382.
24. Clement S, Velasco PT, Murthy SN, et al. The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase [J]. J Biol Chem,1998, 273(13):7604-7609.
25. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures [J]. Invest Ophthalmol Vis Sci, 1999,40(12):2780-2787.
26. Olivero DK, Furcht LT. Type IVcollagen, laminin and fibronectin promote the adhesion and migration of rabbit lens epithelial cells in vitro [J]. Invest Ophthalmol Vis Sci,1993, 34(10):2825-2834.
27. Futter CE, Crowston JG, Allan BD. Interaction with collagen IV protects lens epithelial cells from Fas-dependent apoptosis by stimulating the production of soluble survival factors [J]. Invest Ophthalmol Vis Sci.2005,46(9):3256-3262.
28. Parmigani CM, Mcavoy J W. The roles of laminin and fibronectin in the development of the lens capsule [J]. Curr Eve Res,1991,10(6):501-511.
29. Nishimoto H. Morphological study of the cataractous lens of the senescence accelerated mouse [J]. Grafe's Arch Clin Exp Ophthalmol,1993,231(1):722-726.
30. Oharazaw H, Ibaraki N, Lin LR, et al. The effects of extracellular matrix on cell attachment, proliferation and migration in a human lens epithelial cell line [J]. Exp Eye Res,1999,69(6):603-610.
31. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
32. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin:a role in TGFβ-dependent matrix deposition [J]. J Cell Sci,2001,114(16):2989-3000.
33. Akimov SS, KrylovD, Fleischman LF, et al. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin [J]. J Cell Biol,2000,148:825-838.
34. Wederell ED, de Iongh RU. Extracellular matrix and integrin signaling in lens development and cataract [J]. Semin Cell Dev Biol,2006,17(6):759-776.
35. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
1. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994; 71(4):402-415.
2. Fire A, Xu S, Monotgomery MK, et al. Potent and specific genetic interference by double-strand RNA in Caenorhabditis elegans [J]. Nature,1998,391(6669):806-811.
3. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J]. Nature,2001,411(6836):494-498.
4. Agami R. RNAi and related mechanisms and their potential use for therapy [J]. Curr Opin Chem Biol,2002,6(6):829-834.
5. Carthew RW. Gene silencing by double-stranded RNA [J]. Curr Opin Cell Biol,2001, 13(2):244-248.
6. Tijsterman M, Plasterk RH. Dicers at RISC:the mechanism of RNAi [J]. Cell,2004, 117(1):1-3.
7. Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells [J]. Ann N Y Acad Sci,2003,1002:56-62.
8. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects [J]. EMBO MolMed,2009,1(3):142-151.
9. Dorsett Y, Tuschl T. siRNAs:applications in functional genomics and potential as therapeutics [J]. Nat Rev Drug Discov,2004,3(4):318-329.
10. Lykke-Andersen K. Regulation of gene expression in mouse embryos and its embryonic cells through RNAi. Mol Biotechnol [J].2006,34(2):271-278.
11. Orlacchio A, Bernardi G, Orlacchio A, et al. RNA interference as a tool for Alzheimer's disease therapy [J]. Mini Rev Med Chem,2007,7(11):1166-1176.
12. Dykxhoorn DM. RNA interference as an anticancer therapy:a patent perspective [J]. Expert Opin Ther Pat,2009,19(4):475-491.
13. Janoria KG, Gunda S, Boddu SH, et al. Novel approaches to retinal drug delivery [J]. Expert Opin Drug Deliv,2007,4(4):371-388.
14. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease [J]. Expert Opin Investig Drugs,2009 Oct,18(10): 1505-1517.
15. Wu CJ, Chan YL. Antiviral applications of RNAi for coronavirus [J]. Expert Opin Investig Drugs,2006,15(2):89-97.
16. Pruijn GJ. The RNA interference pathway:a new target for autoimmunity [J]. Arthritis ResTher,2006,8(4):110.
17. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs [J]. Nat Rev Genet,2002,3(10):737-747.
18. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
19. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states [J]. Pharmacol Ther,2007,115(2):232-245.
1. Spalton D J. Posterior capsular opacification after cataract surgery [J]. Eye,1999; 13: 489-492.
2. Lois N, Taylor J, McKinnon AD, et al. Effect of TGF-beta2 and anti-TGF-beta2 antibody in a new in vivo rodent model of posterior capsule opacification [J]. Invest Ophthalmol Vis Sci,2005,46(11):4260-4266.
3. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification [J]. Exp Eye Res, 2009,88(2):257-269.
4. Aeschlimann D, Paulsson M. Protein Cross-Linking Enzymes in Tissues and Body Fluids [J]. Thromb Haemost,1994; 71(4):402-415.
5. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005; 179(1-2):43-55.
6. Shigemitsu T, Ishiguro K, Shimizu Y, et al. Immunocytochemical features of lens after cataract tissue-signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins [J]. Int Ophthalmol,1999,23(3):137-144.
7. Kurosaka D, Kato K, Nagamoto T, et al. Growth factors influence contractility and alpha-smooth muscle actin expression in bovine lens epithelial cells [J]. Invest Ophthalmol Vis Sci,1995,36(8):1701-1708.
8. Wang XL, Zhang JS, Yu T. Laminin and fibronectin influence growth characteristics of human lens epithelial cells in vitro [J]. Zhonghua Yan Ke Za Zhi,2005,41(4): 340-345.
9. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
10. Liu J, Hales AM, Chamberlain CG, et al. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci, 1994,35(2):388-401.
11. Gordon-Thomson C, de Iongh RU, Hales AM, et al. Differential cataractogenic potency of TGF-betal,-beta2, and-beta3 and their expression in the postnatal rat eye [J]. Invest Ophthalmol Vis Sci,1998,39(8):1399-1409.
12. Lovicu FJ, Schulz MW, Hales AM, et al. TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract [J]. Br J Ophthalmol, 2002,86(2):220-226.
13. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36:1709-1713.
14. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis Sci.2002; 43(7):2301-2308.
15. Schnabel C, Sawitza I, Tag C G, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28:140-145.
16. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-betal mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J]. Mol Biol Cell 2001,12:27-36.
17. Cho HJ, Yoo J. Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells [J]. Cell Biol Int,2007, 31(10):1225-1230.
18. Wittinghofer F. Ras signaling. Caught in the act of the switch-on [J]. Nature,1998,394: 317-320.
19. Masszi A, Diciano C, Sirokmany G, et al. Central role for Rho in TGF-betal-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition [J]. Am J Physiol Renal Physiol,2003,284:911-924.
20. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase Ⅱ in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
21. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes Rho A activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway [J]. Mol Biol Cell,2006,17(4):1606-1619.
22. Olivero DK, Furcht LT. Type IV collagen, laminin, and fibronectin promote the adhesion and migration of rabbit lens epithelial cells in vitro [J]. Invest Ophthalmol Vis Sci,1993,34(10):2825-2834.
23. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J]. Nature,2001,411:494-498.
24. Dorsett Y, Tuschl T. siRNAs:applications in functional genomics and potential as therapeutics [J]. Nat Rev Drug Discov,2004,3(4):318-329.
25.陈春林.RNA干扰技术及其在眼科疾病中的应用[J].眼科新进展,2008,28(1)：60-64.
1. Clarke DD, Mycek MJ, Neidle A, et al. The Incorporation of Amines into Protein [J]. Arch BiochemBiophys,1959,79:338-354.
2. Lorand L, Graham RM. Transglutaminases:crosslinking enzymes with pleiotropic functions [J]. Nat Rev Mol Cell Biol,2003,4(2):140-156.
3. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study [J]. Cell Tissue Res,1989,255:215-224.
4. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications [J]. Amino Acids,2009,36(4): 659-670.
5. Mhaouty-Kodja S. Ghalpha/tissue transglutaminase 2:an emerging G protein in signal transduction [J]. Biol Cell,2004,96(5):363-367.
6. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival [J]. FEBS Lett,2005,579(15):3297-3302.
7. Kim SY. Transglutaminase 2 in inflammation [J]. Front Biosci,2006,11:3026-3035.
8. Elli L, Bergamini CM, Bardella MT, et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver [J]. Dig Liver Dis,2009,41(8): 541-550.
9. Hoffner G, Djian P. Transglutaminase and diseases of the central nervous system [J]. Front Biosci,2005,10:3078-3092.
10. Molberg O, McAdam SN, Sollid LM. Role of tissue transglutaminase in celiac disease [J]. J Pediatr Gastroenterol Nutr,2000,30(3):232-240.
11. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and vascular diseases [J]. Front Biosci,2007,12:2530-2545.
12. Mangala LS, Mehta K. Tissue transglutaminase(TG2) in cancer biology [J]. Prog Exp Tumor Res,2005,38:125-138.
13. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
14. Tovar-Vidales T, Roque R, Clark AF, et al. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues [J]. Invest Ophthalmol Vis Sci,2008,49(2):622-628.
15. Priglinger SG, May CA, Neubauer AS, et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes [J]. Invest Ophthalmol Vis Sci, 2003,44(1):355-364.
16. Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity [J]. Proc Natl Acad Sci,2002,99(5):2743-2747.
17. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases:multifunctional cross-linking enzymes that stabilize tissues [J]. FASEB J,1991,5(15):3071-3077.
18. Samuelsson B, Stenberg P, Pandolfi M. Localization and characteristics of transglutaminase in the rabbit and human eye [J]. Graefes Arch Clin Exp Ophthalmol, 1982,218(5):233-236.
19. Chen JSK, Mehta K. Tissue transglutaminase:an enzyme with a split personality [J]. Int JBiochem Cell Biol,1999,31(8):817-836.
20. Hang J, Zemskov EA, Lorand L, et al. Identifiction of a Novel Recognition Sequence for Fibronectin within the NH2-terminal β-Sandwich Domain of Tissue Transglutaminase [J]. J Biol Chem,2005,280(25):23675-23683.
21. Verderio E, Nicholas B, Gross S, et al. Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts:effects on the processing of fibronectin, cell attachment, and cell death [J]. Exp Cell Res,1998,239(1):119-138.
22. Folk JE. Transglutaminases [J]. Annu Rev Biochem,1980,49:517-531.
23. Lee KN, Arnold SA, Birckbichler PJ, et al. Site-directed mutagenesis of human tissue transglutaminase:Cys-277 is essential for transglutaminase activity but not for GTPase activity [J]. Biochim Biophys Acta,1993,1202(1):1-6.
24. Griffin M, Casadio R, Bergamini CM. Transglutaminases:nature's biological glues [J]. Biochem J,2002,368:377-396.
25. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
26. Verma A, Mehta K. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells:a new therapeutic opportunity [J]. Curr Cancer Drug Targets,2007,7(6):559-565.
27. Peng X, Zhang Y, Zhang H, et al. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3 [J]. FEBS Lett,1999,446(1):35-39.
28. Kim JH, Nam KH, Kwon OS, et al. Histone cross-linking by transglutaminase [J]. Biochem Biophys Res Commun,2002,293(5):1453-1457.
29. Casadio R, Polverini E, Mariani P, et al. The structural basis for the regulation of tissue transglutaminase by calcium ions [J]. Eur J Biochem,1999,262(3):672-679.
30. Jeon JH, Cho SY, Kim CW, et al. GTP is required to stabilize and display transamidation activity of transglutaminase 2 [J]. Biochem Biophys Res Commun, 2002,294(4):818-822.
31. Chen S, Lin F, Iismaa S, et al. Alphal-adrenergic receptor signaling via Gh is subtype specific and independent of its transglutaminase activity. J Biol Chem,1996,271(50): 32385-32391.
32. Goodhardt M, Ferry N, Aggerbeck M, et al. The hepatic alpha 1-adrenergic receptor [J]. Biochem Pharmacol,1984,33(6):863-868.
33. Nakaoka H, Perez DM, Baek KJ, et al. Gh:a GTP-binding protein with transglutaminase activity and receptor signaling function [J]. Science,1994, 264(5165):1593-1596.
34. Stephens P, Grenard P, Aeschlimann P, et al.Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses [J]. J Cell Sci,2004,117(15):3389-3403.
35. O'toole TE, Katagiri Y, Faull RJ, et al. Integrin cytoplasmic domains mediate inside-out signal transduction[J]. JCellBiol,1994,124(6):1047-1059.
36. Ekblom P, Timpl R. Cell-to-cell contact and extracellular matrix. A multifaceted approach emerging [J]. Curt Opin Cell Biol,1996,8(5):599-601.
37. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp:a versatile cell recognition signal [J]. Cell,1986,44(4):517-518.
38. Bloor DJ, Metcalfe AD, Rutherford A, et al. Expression of cell adhesion molecules during human preimplantation embryo development [J]. Mol Hum Reprod,2002,8(3): 237-245.
39. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion [J]. Curr Opin Cell Biol,2007,19(5):495-507.
40. Moissoglu K, Schwartz MA. Integrin signalling in directed cell migration [J]. Biol Cell, 2006,98(9):547-555.
41. Dean DC, Iademarco MF, Rosen GD, et al. The integrin alpha 4 beta 1 and its counter receptor VCAM-1 in development and immune function [J]. Am Rev Respir Dis,1993, 148:43-46.
42. Grinnell F. Wound repair, keratinocyte activation and integrin modulation [J]. J Cell Sci, 1992,101(1):1-5.
43. Akimov, SS, Krylov D, Fleischman, LF. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin [J]. Cell Biol,2000,148,825-838.
44. Sechler JL, Schwarzbauer JE. Control of cell cycle progression by fibronectin matrix architecture [J]. J Biol Chem,1998,273(40):25533-25536.
45. Hadden HL, Henke CA. Induction of lung fibroblast apoptosis by soluble fibronectin peptides [J]. Am J Respir Crit Care Med,2000,162:1553-1560.
46. Jeong J, Han I, Lim Y, et al. Rat embryo fibroblasts require both the cell-binding and the heparin-binding domains of fibronectin for survival [J]. Biochem J,2001,356(2): 531-537.
47. Sharma A, Askari JA, Humphries MJ, et al. Crystal structure of a heparin-and integrin-binding segment of human fibronectin [J]. EMBO J,1999,18(6):1468-1479.
48. Zemskov EA, Janiak A, Hang J, et al. The role of tissue transglutaminase in cellmatrix interactions [J]. Front Biosci,2006,11:173-185.
49. Takahashi H, Isobe T, Horibe S, et al. Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1 [J]. J Biol Chem,2000,275(31):23589-23595.
50. Balklava Z, Verderio E, Collighan R, et al. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts [J]. Biol Chem,2002,277:16567-16575.
51. Verderio EA, Telci D, Okoye A, et al. A novel RGD-independent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis [J]. J Biol Chem,2003,278(43):42604-42614.
52. Burridge K, Wennerberg K. Rho and Rac take center stage [J]. Cell,2004,116(2): 167-179.
53. Wittinghofer F. Ras signaling. Caught in the act of the switch-on [J]. Nature,1998,394: 317-320.
54. Loirand G, Guerin P, Pacaud P, et al. Rho kinases in cardiovascular physiology and pathophysiology [J]. Circ Res,2006,98(3):322-334.
55. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [J]. Science,1996,273 (5272):245-248.
56. Singh US, Kunar MT, Kao YL, et al. Role of transglutaminase II in retinoic acid-induced activation of RhoA-associated kinase-2 [J]. EMBO J,2001,20(10): 2413-2423.
57. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway [J]. Mol Biol Cell,2006,17(4):1606-1619.
58. Redding GS, Record DM, Raess BU. Calcium-stressed erythrocyte membrane structure and function for assessing glipizide effects on transglutaminase activation [J]. Proc Soc Exp Biol Med,1991,196(1):76-82.
59. Telci D, Collighan RJ, Basaga H, et al. Increased TG2 expression can result in induction of transforming growth factor betal, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide [J]. J Biol Chem, 2009,284(43):29547-29558.
60. Monsonego A, Friedmann I, Shani Y, et al.GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase [J]. J Mol Biol,1998,282(4):713-720.
61. Lee SC, Kim JH, Park ES, et al. Ca2+:a stabilizing component of the transglutaminase activity of Galphah (transglutaminase II). Mol Cells,2003,16(3):285-290.
62. Ishii I, Ui M. Retinoic acid-induced gene expression of tissue transglutaminase via protein kinase C-dependent pathway in mouse peritoneal macrophages [J]. J Biochem, 1994,115(6):1197-1202.
63. Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB [J]. Am J Physiol,1997,272:281-288.
64. Jung SA, Lee HK, Yoon JS, et al. Upregulation of TGF-beta-induced tissue transglutaminase expression by PI3K-Akt pathway activation in human subconjunctival fibroblasts [J]. Invest Ophthalmol Vis Sci,2007,48(5):1952-1958.
65. Kuncio GS, Tsyganskaya M, Zhu J, et al. TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells [J]. Am J Physiol,1998,274:240-245.
66. Johnson K, Hashimoto S, Lotz M, et al. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor ⅩⅢa [J]. Am J Pathol,2001,159(1): 149-163.
67. Ikura K, Shinagawa R, Suto N, et al. Increase caused by interleukin-6 in promoter activity of guinea pig liver transglutaminase gene [J]. Biosci Biotechnol Biochem, 1994,58(8):1540-1541.
68. Fraij BM, Gonzales RA. Organization and structure of the human tissue transglutaminase gene [J]. Biochim Biophys Acta,1997,1354(1):65-71.
69. Lu S, Saydak M, Gentile V, et al. Isolation and characterization of the human tissue transglutaminase gene promoter. J Biol Chem.1995,270(17):9748-9756.
70. Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer [J]. Carcinogenesis,2008,29(3):510-518.
71. Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response [J]. Amino Acids,2007,33(2):385-394.
72. Medina MA. Glutamine and cancer [J]. J Nutr,2001,131:2539-2542.
73. Autuori F, Farrace MG, Oliverio S, et al. "Tissue" transglutaminase and apoptosis [J]. Adv Biochem Eng Biotechnol,1998,62:129-136.
74. Rodolfo C, Mormone E, Matarrese P, et al. Tissue transglutaminase is a multifunctional BH3-only protein [J]. J Biol Chem,2004,279(52):54783-54792.
75. Robitaille K, Daviau A, Lachance G, et al. Calphostin C-induced apoptosis is mediated by a tissue transglutaminase-dependent mechanism involving the DLK/JNK signaling pathway [J]. Cell Death Differ,2008,15(9):1522-1531.
76. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis:evidence for incomplete resolution associated with matrix cross-linking [J]. Gastroenterology,2004,126:1795-1808.
77. Hwang JY, Mangala LS, Fok JY, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma [J]. Cancer Res,2008,68(14):5849-5858.
78. Kim DS, Park KS, Kim SY. Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors [J]. Front Biosci,2009,14:2514-2521.
79. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells [J]. Drug Resist Updat,2007,10(4-5):144-151.
80. Yamaguchi H, Wang HG. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells [J]. Mol Cell Biol,2006, 26(2):569-579.
81. Clement S, Velasco PT, Murthy SN, et al. The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase [J]. J Biol Chem,1998, 273(13):7604-7609.
82. Raghunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures [J]. Invest Ophthalmol Vis Sci,1999,40(12):2780-2787.
83. Roberts AB. Molecular and cell biology of TGF-beta [J]. Miner Electrolyte Metab, 1998,24(2-3):111-119.
84. Nunes I, Gleizes PE, Metz CN, et al. Latent transforming growth factor-beta binding protein domains involved in actvation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta [J]. J Cell Biol,1997,136(5):1151-1163.
85. Antonyak MA, Li B, Regan AD, et al. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem.2009,284(27):17914-17925.
86. Stephens P, Grenard P, Aeschlimann P, et al. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses [J]. J Cell Sci,2004,117(15):3389-3403.
87. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [J]. Science,1996,273(5272):245-248.
88. Kalluri R. EMT:when epithelial cells decide to become mesenchymal-like cells [J]. J Clin Invest,2009,119(6):1417-1419.
89. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer:do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem,2007,101(4):830-839.
90. Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-betal mediates epithelial to mesenchymal-transdifferentiation through a RhoA-dependent mechanism [J]. Mol Biol Cell,2001,12:27-36.
91. Patel S, Takagi KI, Suzuki J, et al. RhoGTPase Activation Is a Key Step in Renal Epithelial Mesenchymal Transdifferentiation. [J]. Am Soc Nephrol 2005,16(7): 1977-1984.
92. Schnabel C, Sawitza I, Tag CG, et al. Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its up-regulation during transdifferentiation to myofibroblasts in culture [J]. Hepatol Res,2004,28: 140-145.
93. Shao M, Cao L, Shen C, et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase [J]. Cancer Res,2009,69(24): 9192-9201.
94. Burton M, Fergusson E, Hart A, et al. The prevalence of cataract in two villages of northern Pakistan with different levels of ultraviolet radiation [J]. Eye (Lond),1997, 11(1):95-101.
95. Duncan G, Jacob TJ. Calcium and the physiology of cataract [J]. Ciba Found Symp, 1984,106:132-152.
96. Lorand L, Hsu LK, Siefring GE Jr, et al. Lens transglutaminase and cataract formation [J]. Proc Natl Acad Sci USA,1981,78(3):1356-1360.
97. Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation:implications of transglutaminase 2 in age-related cataractogenesis [J]. J Biol Chem,2004,279(15): 15032-15039.
98. Velasco PT, Murthy P, Goll DE, et al. Cross-linking and proteolysis in Ca2(+)-treated lens homogenates [J]. Biochim Biophys Acta,1990,1040(2):187-191.
99. Andley UP. Effects of alpha-crystallin on lens cell function and cataract pathology [J]. Curr Mol Med,2009,9(7):887-892.
100. de longh RU, Wederell E, Lovicu FJ, et al. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens:a model for cataract formation [J]. Cells Tissues organs,2005; 179(1-2):43-55.
101. Parmigani CM, Mcavoy J W. The roles of laminin and fibronectin in the development of the lens capsule [J]. Curr Eve Res,1991,10(6):501-511.
102. de Jong-Hesse Y, Kampmeier J, Lang GK, et al. Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells [J]. Graefes Arch Clin Exp Ophthalmol,2005,243(7):695-700.
103. Liu J, Hales AM, Chamberlain CG, et al. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta [J]. Invest Ophthalmol Vis Sci, 1994,35(2):388-401.
104. Gordon-Thomson C, de Iongh RU, Hales AM, et al. Differential cataractogenic potency of TGF-betal,-beta2, and-beta3 and their expression in the postnatal rat eye [J]. Invest Ophthalmol Vis Sci,1998,39(8):1399-1409.
105. Hales AM, Chamberlain CG, McAvoy JW, et al. Cataract induction in lenses cultured with transforming growth factor-beta [J]. Invest Ophthalmol Vis Sci,1995,36: 1709-1713.
106. Wormstone IM, Tamiya S, Anderson I, et al. TGF-beta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag [J]. Invest Ophthalmol Vis Sci.2002; 43(7):2301-2308.
107. Wan XH, Lee EH, Koh HJ, et al. Enhanced expression of transglutaminase 2 in
anterior polar cataracts and its induction by TGF-β in vitro [J]. Br J Ophthalmol,2002, 86:1293-1298.
108. Knepper PA, Goossens W, Palm berg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma [J]. Invest Ophthalmol Vis Sci, 1996,37(5):1360-1367.
109. Tovar-Vidales T, Roque R, Clark AF, et al. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues [J]. Invest Ophthalmol Vis Sci,2008,49(2):622-628.
110. Stefan C, Dragomir L, Dumitrica DM, et al. TGF-beta2 involvements in open angle glaucoma. Oftalmologia,2008,52(3):110-112.
111. Priglinger SG, Alge CS, Kook D, et al. Potential role of tissue transglutaminase in glaucoma filtering surgery [J]. Invest Ophthalmol Vis Sci,2006,47(9):3835-3845.
112. Hiscott P, Sheridan C, Magee RM, et al. Matrix and the retinal pigment epithelium in proliferative retinal disease [J]. Prog Retin Eye Res,1999,18(2):167-190.
113. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye [J]. J Clin Invest,1989,83(5):1661-1666.
114.王辉,刘哲丽,郝旭红等.增生性玻璃体视网膜病变中组织型转谷氨酰胺酶的表达[J].国际眼科杂志,2007,2(7)：392-394.
115. Priglinger SG, May CA, Neubauer AS, et al. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes [J]. Invest Ophthalmol Vis Sci, 2003,44(1):355-364.
116. Priglinger SG, Alge CS, Neubauer AS, et al. TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain [J]. Invest Ophthalmol Vis Sci,2004,45(3): 955-963.
117. Tamai M. Progress in pathogenesis and therapeutic research in retinitis pigmentosa and age-related macular degeneration. Nippon Ganka Gakkai Zasshi,2004,108(12):
750-768.
118. Zhang SR, Li SH,Abler A, et al. Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina [J]. Invest Ophthalmol Vis Sci,1996,37:1793-1799.
119. Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases:from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes [J]. Hum Mol Genet,2002,11(20):2371-2375.
120. Sohn J, Chae JB, Lee SY, et al. A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor [J]. Korean J Ophthalmol,2010,24(1):29-34.